CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
CLN-617-001 is a Phase 1, open-label, dose escalation, dose optimization and dose expansion
study of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid
tumors